Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%

Intervention not reported

Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, dimethylfumarate, fingolimod, glatiramer acetate,…

It is very uncertain whether the intervention changes ofatumumab No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
RR 0.54 [0.38, 0.77]
Studies not reported
Very low

Intervention not reported

Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, azathioprine, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate,…

The intervention may leads to higher ofatumumab No direct evidence (low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
OR 2 [1.05, 3.81]
Studies not reported
Low

Intervention not reported

Ofatumumab No direct evidence · Patients with RRMS Interventions: Alemtuzumab, cladribine, daclizumab, dimethylfumarate, fingolimod, glatiramer acetate, interferon…

It is very uncertain whether the intervention changes ofatumumab No direct evidence (very low certainty).

1 finding from 1 review

Immunomodulators and immunosuppressants for relapsing‐remitting multiple sclerosis: a network meta‐analysis 2024 · Cochrane Headline outcomes only
OR 1.52 [0.89, 2.57]
Studies not reported
Very low